Edoxaban: Difference between revisions
ClaireLewis (talk | contribs) |
(Text replacement - "w/ " to "with ") |
||
(3 intermediate revisions by 3 users not shown) | |||
Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Thromboembolism]]/[[stroke]] Prophylaxis=== | |||
*60 mg PO QD | |||
===[[DVT]]/[[PE]] Treatment=== | |||
*<60 kg | |||
**30 mg PO QD | |||
*>60 kg | |||
**60 mg PO QD | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Line 26: | Line 27: | ||
***CrCl > 95: Avoid Use | ***CrCl > 95: Avoid Use | ||
***CrCl 50-95: No Adjustment | ***CrCl 50-95: No Adjustment | ||
***CrCl 15-50: 30 mg | ***CrCl 15-50: 30 mg QD | ||
***CrCl <15 (not on HD): Avoid use | ***CrCl <15 (not on HD): Avoid use | ||
**DVT/PE treatment | **[[DVT]]/PE treatment | ||
***CrCl 15-30: 30 mg | ***CrCl 15-30: 30 mg QD | ||
***Cr Cl <15 (not on HD): Avoid use | ***Cr Cl <15 (not on HD): Avoid use | ||
*Pediatric: N/A | *Pediatric: N/A | ||
Line 67: | Line 68: | ||
==Comments== | ==Comments== | ||
*Black Box Warnings: | *Black Box Warnings: | ||
**Reduced Efficacy in non-valvular Afib Pts | **Reduced Efficacy in non-valvular Afib Pts with CrCl >95mL/min with increased risk for ischemic stroke | ||
**Premature treatment discontinuation increases the risk of increased ischemic event for reasons other than pathological bleeding or course completion | **Premature treatment discontinuation increases the risk of increased ischemic event for reasons other than pathological bleeding or course completion | ||
**Epidural/Spinal Hematoma Risk after anesthesia or spinal puncture may result in long-term or permanent paralysis and increases. | **Epidural/Spinal Hematoma Risk after anesthesia or spinal puncture may result in long-term or permanent paralysis and increases. |
Revision as of 01:13, 24 July 2017
Administration
- Type: Anticoagulant
- Dosage Forms: 15, 30, 60 mg
- Routes of Administration: Oral
- Common Trade Names: Savaysa
Adult Dosing
Thromboembolism/stroke Prophylaxis
- 60 mg PO QD
DVT/PE Treatment
- <60 kg
- 30 mg PO QD
- >60 kg
- 60 mg PO QD
Pediatric Dosing
N/A
Special Populations
- Pregnancy Rating: D; Avoid use (Risk of maternal hemorrhage and embryo-fetal death up to 49xMRHD based on animal data and risk of maternal/fetal bleeding base don mechanism of action; No known risk of teratogenicity)
- Lactation risk: L3; Safety unknown
Renal Dosing
- Adult:
- Thromboembolism/stroke Prophylaxis
- CrCl > 95: Avoid Use
- CrCl 50-95: No Adjustment
- CrCl 15-50: 30 mg QD
- CrCl <15 (not on HD): Avoid use
- DVT/PE treatment
- CrCl 15-30: 30 mg QD
- Cr Cl <15 (not on HD): Avoid use
- Thromboembolism/stroke Prophylaxis
- Pediatric: N/A
Hepatic Dosing
- Adult: Child-Pugh Class B or C: Avoid use
- Pediatric: N/A
Contraindications
- Allergy to class/drug
- Hypersenstivity to drug/class/component
- Active major bleeding
- CrCl > 95 (non-valvular atrial fibrillation patients)
- CrCl < 15
- Hepatic impairment (Child-Pugh Class B or C)
Adverse Reactions
Serious
- Epidural hematoma
- Bleeding, severe
- Thrombosis with premature D/C
Common
Pharmacology
- Half-life: 10-14 hr
- Metabolism: Minimal; CYP450: 3A4 substrate
- Excretion: Urine 50%
Mechanism of Action
Factor Xa inhibitor
Comments
- Black Box Warnings:
- Reduced Efficacy in non-valvular Afib Pts with CrCl >95mL/min with increased risk for ischemic stroke
- Premature treatment discontinuation increases the risk of increased ischemic event for reasons other than pathological bleeding or course completion
- Epidural/Spinal Hematoma Risk after anesthesia or spinal puncture may result in long-term or permanent paralysis and increases.